Helicobacter Pylori Infections Treatment Market to expand at a 7.04% value CAGR by 2033

rise in the prevalence of Helicobacter pylori infection, higher demand for early recognition of symptoms, and advancements in diagnostic methods all contribute to the market's growth.

According to forecasts, the global market for treating Helicobacter pylori infections is expected to reach a value of US$ 638.3 million by 2023, and is projected to have a compound annual growth rate (CAGR) of 7.04% from 2023 to 2033, resulting in a total value of US$ 1,260 million. Factors such as inadequate water supply, poor sanitation, large population, and insufficient personal hygiene are contributing to the spread of this infection. Increased awareness of H. pylori infections is one of the driving factors for the growth of the Helicobacter pylori diagnostics market.

The use of antibiotics is expected to increase due to the availability and affordability of antibiotics, as well as faster processing times, leading to a higher demand for pre and post-surveillance tests. Additionally, the need for early symptom detection, technological advancements in diagnostic techniques, and the rising rate of H. pylori infections are expected to drive overall growth in the forecast period.

Request Sample Copy of Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16291

The main drivers of the industry are the increasing prevalence of communicable diseases and greater public awareness of infections such as tuberculosis, Chlamydia, gonorrhea, other sexually transmitted diseases (STDs), stomach flu (gastroenteritis), and urinary tract infections (UTIs). During the forecast period, North America is expected to dominate the global Helicobacter pylori diagnostics market due to factors such as an increase in disease transmission, greater awareness of communicable diseases, and the launch of new products.

Key Takeaways from Market Study

• Global helicobacter pylori treatment market to expand nearly 2x from 2023 to 2033
• By 2023, Europe is expected to have the second-highest H. pylori sales volume, with 30% revenue.
• In terms of total revenue, hospitals and diagnostics laboratories accounted for more than 82% of the industry share in 2021.
• The global helicobacter pylori infections market is expected to be worth US$ 1,260 Million
• The global market for helicobacter pylori infections is estimated to be worth US$ 638.3 Million

“With a rise in the prevalence of chronic diseases, demand for helicobacter pylori treatment is rising, paving way for new approaches to treatment and therapeutics,” remarks an analyst at FMI.

Ask Our Analyst More About Report@ https://www.futuremarketinsights.com/ask-question/rep-gb-16291

Market Competition

Key players in the Helicobacter Pylori Infections Market are:

• Phathom Pharmaceuticals
• Redhill Biopharma
• Takeda Pharmaceuticals
• AbbVie
• Cumberland Pharmaceuticals
• Eisai Co.
• Bio-Rad Laboratories
• F. Hoffmann-La Roche
• Alpha Laboratories
• Biohit

• In May 2022, Biomerica, Inc. received CE Mark for its hp+detect diagnostic test for Helicobacter pylori bacteria. Following product registration in each nation where it is sold, the company plans to market and sell its hp+detect diagnostic test in the European Union (EU) and other international markets.
• Otsuka launched QuickNavi^TM-H. Pylori, a Helicobacter pylori Quick Detection Kit, in April 2021. The diagnostic kit employs the immunochromatography technique to determine the presence or absence of Helicobacter pylori antigens in a stool sample.
• In July 2022, Bio Rad introduced Platelia H. pylori IgG, an immuno-enzymatic assay for qualitative determination of IgG antibodies. Serology is a non-invasive, delicate, and simple method for determining H. pylori infection. To evaluate the quality of IgG antibodies, the Platelia H. pylori IgG immunoenzymatic assay is used.

Want More Insights:

North America is the largest helicobacter pylori infections market due to the high prevalence of the infection in the region. The United States dominates the market in North America, with a large patient population and well-established healthcare infrastructure. The country has also approved several drugs for the treatment of H. pylori infections, such as clarithromycin, amoxicillin, and metronidazole.

Buy Complete Report@ https://www.futuremarketinsights.com/checkout/16291

Key Segments Profiled in the Helicobacter Pylori Infections Treatment Market Industry Survey 

By Treatment:

• Bismuth-quadruple Therapy
• Concomitant Therapy
• Levofloxacin Triple Therapy
• Bismuth Therapy
• High-dose Dual Therapy

By Application:

• Hospitals
• Diagnostics Laboratories
• Clinics